EXPANSION OF LYMPHOCYTE WITH A CYTOKINE COMPOSITION FOR ACTIVE CELLULAR IMMUNOTHERAPY Russian patent published in 2020 - IPC A61K38/19 A61K35/14 A61P35/00 A61P31/00 A61P37/00 C12N5/07 G01N33/50 

FIELD: cellular immunotherapy.

SUBSTANCE: invention relates to a composition for expanding lymphocyte, a method of producing a population of clinically significant lymphocytes, to a method of treating or preventing diseases in a mammal (versions), to using a kit in immunotherapy, to a clinically significant lymphocyte (versions), to a population of clinically significant lymphocytes (versions). Composition for lymphocyte expansion contains interleukin-2 (IL-2), interleukin-15 (IL-15) and interleukin-21 (IL-21) in certain concentrations, wherein the composition is in a liquid form. Method for producing a population of clinically significant lymphocytes involves a number of steps: obtaining a tissue sample or body fluid sample, body in vitro culture of the sample for expansion and/or stimulation of lymphocytes in the sample, wherein the culturing involves using IL-2, IL-15 and IL-21 taken in certain concentrations, determining the presence of a clinically significant lymphocyte in the cultured sample. Method of treating or preventing a malignant disease in a mammal, involving certain stages. Method of treating or preventing an infectious disease in a mammal, involving certain stages. Method of treating or preventing an autoimmune disease in a mammal, involving certain stages. Use of kit in immunotherapy, where kit contains IL-2, IL-15 and IL-21, taken in certain concentrations, in liquid composition, a component which stimulates TCR-costimulatory molecules, feeder cells and a peptide comprising a sequence of at least one clinically significant antigen. Clinically significant lymphocyte obtained by said method (versions). Population of clinically significant lymphocytes obtained by the above method (versions).

EFFECT: described above enables to ensure successful expansion of lymphocytes against a variety of different tumors due to the developed agents and methods for obtaining a product of expanded lymphocytes with improved composition of T-cell phenotypes for effective ACT applicable for other types of tumors.

38 cl, 18 tbl, 42 ex, 33 dwg